Clinical Trials Logo

Hemorrhage clinical trials

View clinical trials related to Hemorrhage.

Filter by:

NCT ID: NCT04579965 Not yet recruiting - Clinical trials for Dysfunctional Uterine Bleeding

Misotac vs Combined Oral Contraceptive Pill in the Treatment of Symptomatic Isthmocele

Start date: October 1, 2020
Phase: N/A
Study type: Interventional

Isthmocele is a growing concern as a cause of abnormal uterine bleeding, especially post menstrual bleeding which may be present in up to 82% of these cases (Iannone et al 2019). our trial is a randomized clinical trial in which women will be randomly allocated to either medical treatment by oral contraceptive or to medical treatment by misotac.

NCT ID: NCT04574128 Not yet recruiting - Clinical trials for Blood Loss, Surgical

Retransfusion or Not of Cardiotomy Blood

Start date: October 1, 2020
Phase: N/A
Study type: Interventional

This randomised controlled trial has a non-inferiority design. The aim is to test if the blood loss (volume in mL and hemoglobin) is effected by heart and lung cardiotomy retransfusion, or not? Forty CABG (Coronary Artery By pass Grafting) patients will be allocated to either receive retransfusion (n=20) of cardiotomy blood via the heart and lung mashine, or no retransfusion (n=20).

NCT ID: NCT04549012 Not yet recruiting - Effect of Drug Clinical Trials

Determination of Blood Loss After CS

Start date: September 2020
Phase: Early Phase 1
Study type: Interventional

Comparing betweeen tranexamic acid plus oxytocin and oxytocin alone in their efficacy in reducing blood loss following CS

NCT ID: NCT04537533 Not yet recruiting - Bleeding Clinical Trials

Tranexamic Acid Infusion in Low Dose Versus in High Dose for Reducing Blood Loss in Radical Cystectomy Operations

Start date: September 2020
Phase: Phase 4
Study type: Interventional

Bladder cancer is one of the most common cancers of the genitourinary tract in adults, and its incidence distinctly increases with age . In almost two-thirds of cases, the disease is superficial at presentation and involves the mucosal and sub mucosal layers or the lamina propria of the bladder, whereas ∼20% to 30% of patients have muscle-invasive tumors. Superficial bladder cancer is treated by transurethral endoscopic resection, which can be followed by endovesical therapy for patients at risk of disease recurrence and progression . In contrast, muscle-invasive bladder cancer is generally treated by radical cystectomy with pelvic lymph node dissection and then creation of urinary diversion to create an alternate route for urine passage, which demonstrates 10-year recurrence-free survival rates of 50% to 59% and overall survival rates of ∼45% . These major surgeries have a prolonged operative times and are associated with significant risk of complications including high risk of perioperative bleeding and subsequent need for blood transfusion with significant postoperative complications, which are reportedly in the range of 24% to 64% .

NCT ID: NCT04532333 Not yet recruiting - Clinical trials for Subarachnoid Hemorrhage, Aneurysmal

Efficacy and Safety of Bivalirudin Versus Heparin During Coil Embolization in Patients With Ruptured Intracranial Aneurysms

BUILD
Start date: August 2020
Phase: Phase 3
Study type: Interventional

This is a randomized, open label, multi-center, positive-controlled study, in which a total of 236 patients will be enrolled and randomly assigned to receive bivalirudin or heparin in a 1:1 ratio during coil embolization in patients with ruptured intracranial aneurysms. Procedure-related complication, mRS, Activated Clotting Time, ischemic and hemorrhagic complications, symptomatic and asymptomatic intracranial hemorrhage, death, Heparin Induced Thrombocytopenia will be evaluated during procedure, at 24hs, 7days and 30 days after.

NCT ID: NCT04524676 Not yet recruiting - Colorectal Cancer Clinical Trials

Oxaliplatin-induced Portal Hypertension

Start date: August 31, 2020
Phase: N/A
Study type: Interventional

Oxaliplatin has been used as the first choice for the adjuvant chemotherapy of colorectal cancer and it has significantly improved the outcomes in patients with colorectal cancer. However, hepatotoxicity is the potentially problematic adverse effect of oxaliplatin. The pathological evaluation of non-tumoral liver from patients with advanced colorectal cancer undergoing neoadjuvant oxaliplatin-based treatment has provided histological evidence of hepatic sinusoidal injury. Oxaliplatin-induced sinusoidal injury can persist for more than 1 year after the completion of chemotherapy, and the increase in splenic volume may be a predictor of irreversible sinusoidal damage. In this current study, we aim to evaluate the efficacy of individualized treatment in patients with oxaliplatin-induced gastroesophageal varices after colorectal cancer surgery.

NCT ID: NCT04515420 Not yet recruiting - Clinical trials for Brain Injuries, Traumatic

The Influence of Noradrenaline on Coagulation and Fibrinolysis in Severe Isolated Brain Injury

Start date: September 1, 2020
Phase:
Study type: Observational

Aim of the study The investigators aim to establish: - Whether noradrenaline (NA) infusion has a significant effect on coagulation and fibrinolysis in patients with severe traumatic brain injury (TBI). - Whether disruption of haemostasis can be recorded with a computerized tomography (CT) scan. - Whether there is a significant difference between the values of haemostasis parameters in the internal jugular vein and the radialis artery. The hypotheses 1. In the early stage of treatment (1-3 hours), an increased formation of thrombin occurs in patients with severe isolated TBI that are treated with NA; consequently, platelet use increases in comparison with patients who don't need NA, as do coagulation factors and hyperfibrinolysis. 2. The concentration of NA correlates with thrombin formation and the correlation is stronger in higher doses of NA. 3. Thrombin formation will decrease more slowly in the group that will receive NA therapy in comparison to the group that will not receive NA therapy.

NCT ID: NCT04512859 Not yet recruiting - Clinical trials for Subarachnoid Hemorrhage, Aneurysmal

Stellate Ganglion Block in Preventing Cerebral Vasospasm Secondary to Subarachnoid Hemorrhage

Start date: September 1, 2020
Phase: N/A
Study type: Interventional

To investigate whether the stellate ganglion block is helpful in relieving cerebral vasospasm during aneurysmal coil embolism surgery. The effect was assessed by Transcranial Doppler (TCD).

NCT ID: NCT04509323 Not yet recruiting - Clinical trials for Neurosensory Disorder

Clinical Study of Huperzine A in the Treatment of Patients With Hypertensive Cerebral Hemorrhage

Start date: August 3, 2020
Phase: Phase 4
Study type: Interventional

1. To evaluate the effectiveness of Huperzine A injection in the treatment of brain injury in patients with hypertensive cerebral hemorrhage; 2. To evaluate the safety of Huperzine A injection in the treatment of brain injury in patients with hypertensive cerebral hemorrhage。

NCT ID: NCT04494126 Not yet recruiting - Blood Loss Clinical Trials

Effect of Perioperative Tranexamic Acid on Blood Loss During Management of Maxillofacial Trauma

Start date: August 15, 2021
Phase: Phase 4
Study type: Interventional

This is a prospective, randomized, double-blind study investigating whether intravenous tranexamic acid has any effect on blood loss during maxillofacial trauma surgery, or the subsequent postoperative sequelae. Intraoperative bleeding and postoperative ecchymosis and edema are objectively rated and complications are noted.